T2R Phenotypic Expression Testing via Agonist Panel
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for reliable methods to stimulate and evaluate the phenotypic expression of chemosensory receptors, such as T2Rs, to predict susceptibility to and clinical course of microbial infections, including respiratory illnesses like COVID-19, as existing methods are inadequate in determining individual responses to bitter taste compounds and their impact on immune function.
Innovation Solution
The method involves stimulating T2Rs with specific agonists to determine phenotypic expression deficits, using test kits that include agonists like phenylthiocarbamide, thiourea, and sodium benzoate, and detecting released products to assess innate immune responses, which can help in treating and preventing respiratory infections by enhancing immune function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing methods are used to evaluate chemosensory receptors, then general assessment is possible, but reliable determination of individual phenotypic expression and susceptibility prediction is inadequate
Solution Approach 1:
The patent applies parameter changes by using multiple agonists with different potencies and specificities (phenylthiocarbamide, thiourea, sodium benzoate, denatonium) to stimulate T2Rs. By varying the chemical parameters of the agonists and measuring differential responses, the method achieves precise phenotypic expression determination and reliable susceptibility prediction that single-agonist methods cannot provide.
2Measurement precision
If T2Rs are stimulated with agonists to determine phenotypic expression, then susceptibility prediction is improved, but the complexity of the testing method increases
Solution Approach 1:
The patent employs a multi-functional testing approach where a panel of agonists serves multiple purposes: phenylthiocarbamide and thiourea assess classic bitter taste response, sodium benzoate evaluates aromatic bitter compounds, and denatonium provides high-potency reference. This universal agonist panel simultaneously determines phenotypic expression, predicts susceptibility, and characterizes receptor functionality, reducing overall testing complexity despite using multiple compounds.
Solution Approach 2:
The testing method is segmented into distinct components: genotype analysis, phenotypic expression assessment using multiple agonists, and clinical correlation. This segmentation allows each component to be optimized independently while maintaining overall system simplicity. The agonist panel is divided into specific subsets targeting different T2R subtypes, enabling modular testing protocols.
3Measurement precision
If multiple agonists are used to stimulate T2Rs, then phenotypic expression assessment is improved, but the time and resources required for testing increase
Solution Approach 1:
The patent implements periodic action through a structured agonist administration sequence. Agonists are presented in a specific order (phenylthiocarbamide, thiourea, sodium benzoate, denatonium) with standardized intervals between applications. This periodic protocol allows systematic assessment of phenotypic expression across multiple agonists while controlling testing time and preventing sensory adaptation, completing the full panel assessment in a standardized timeframe.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the accurate prediction of susceptibility to respiratory infections and the clinical course of diseases like COVID-19 by correlating T2R phenotypic expression with infection outcomes, enabling targeted treatments to boost innate immune responses and reduce disease severity.
Implementation Method 1
All of the chemosensory receptor proteins are G-protein coupled receptors. Stimulation of T2Rs activates, at least, the canonical taste signaling cascade involving phospholipase Cβ2 (PLCβ2) and transient receptor potential cation channel subfamily M member 5
Implementation Method 2
Stimulation of T2Rs activates, at least, the canonical taste signaling cascade involving phospholipase Cβ2 (PLCβ2)
Data Source
AI summary
This disclosure provides methods of treating a human subject by stimulating chemosensory receptors, such as T2Rs, to increase level of phenotypic expression. Methods may include detecting phenotypic expression deficit by introducing a first agonist capable of first stimulating the chemosensory receptors by first binding thereto; detecting first stimulating; identifying a first deficit in relation to a first reference level, the first deficit being an instance of phenotypic expression deficit. Second stimulating with a second agonist may reduce the phenotypic expression deficit. Third stimulating with a therapeutic agonist may clear a respiratory illness condition by producing innate immune response.